Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study. (Q36023946)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

title

Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

Ann-Sofie Schauwvlieghe

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

Tunde Peto

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

author name string

G Dijkman

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

J M Hooymans

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

F D Verbraak

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

C B Hoyng

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

M G W Dijkgraaf

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

J R Vingerling

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

R O Schlingemann

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

language of work or name

English

0 references

publication date

20 May 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

page(s)

e0153052

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

2 April 2020

copyright license

start time

20 May 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Ranibizumab for neovascular age-related macular degeneration

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Role of growth factors and the wound healing response in age-related macular degeneration

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

What is new in the management of wet age-related macular degeneration?

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Comparison of retinal nerve fiber layer thickness measurements by spectral-domain optical coherence tomography systems using a phantom eye model

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Pharmacokinetics of intravitreal ranibizumab (Lucentis).

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4874598

Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27203434

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The prevalence of age-related maculopathy in the Rotterdam Study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27203434

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pharmacokinetics of intravitreal bevacizumab (Avastin)

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27203434

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0153052

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27203434 AND SRC:MED&resulttype=core&format=json

2 April 2020

PubMed publication ID

27203434

1 reference